References
- 1. Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016;4, p CD001750. doi:10.1002/14651858.CD001750.pub4 Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/27126581.
- 2. Dong J, Wang Y, Chai WR, Hong QQ, Wang NL, Sun LH, Kuang HP. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial. BJOG. 2017;124(7):1048-1055. doi:10.1111/1471-0528.14622 Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28276192.10.1111/1471-0528.1462228276192
- 3. Ubaldi FM, Capalbo A, Vaiarelli A, Cimadomo D, Colamaria S, Alviggi C, Rienzi L. Follicular versus luteal phase ovarian stimulation during the same menstrual cycle (DuoStim) in a reduced ovarian reserve population results in a similar euploid blastocyst formation rate: new insight in ovarian reserve exploitation. Fertil Steril. 2016;105(6):1488-1495 e1481. doi:10.1016/j.fertnstert.2016.03.002 Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/27020168.10.1016/j.fertnstert.2016.03.00227020168
- 4. Zhu X, Ye H, Fu Y. The Utrogestan and hMG protocol in patients with polycystic ovarian syndrome undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments. Medicine (Baltimore. 2016;95(28):e4193. doi:10.1097/MD.0000000000004193 Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/27428219.10.1097/MD.0000000000004193495681327428219
- 5. Zhu X, Ye H, Fu Y. Comparison of neonatal outcomes following progesterone use during ovarian stimulation with frozen-thawed embryo transfer. Sci Rep. 2017;7(1):7835. doi:10.1038/s41598-017-08472-2 Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28798414.10.1038/s41598-017-08472-2555282428798414
- 6. Yildiz S, Turkgeldi E, Angun B, Eraslan A, Urman B, Ata, B. Comparison of a novel flexible progestin primed ovarian stimulation protocol and the flexible gonadotropin-releasing hormone antagonist protocol for assisted reproductive technology. Fertil Steril. 2019;112(4):677-683. doi:10.1016/j.fertnstert.2019.06.009 Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/31371053.10.1016/j.fertnstert.2019.06.00931371053
- 7. Zhu X, Ye H, Fu Y. Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation. Fertil Steri. 2017;108(3):505-512 e502. doi:10.1016/j.fertnstert.2017.06.017 Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28697910.10.1016/j.fertnstert.2017.06.01728697910
- 8. Guo YC, Chen PY, Li TT, Jia L, Sun P, Zhu WS. Liang X. Y. Different progestin-primed ovarian stimulation protocols in infertile women undergoing in vitro fertilization/intracytoplasmic sperm injection: an analysis of 1188 cycles. Arch Gynecol Obstet. 2019;299(4):1201-1212. doi:10.1007/s00404-019-05065-4 Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/30852654.10.1007/s00404-019-05065-430852654
- 9. Yu S, Long H, Chang HY, Liu Y, Gao H, Zhu J, Ai A. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Hum Reprod. 2018;33(2):229-237. doi:10.1093/humrep/dex367 Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/29300975.10.1093/humrep/dex36729300975
- 10. Zhu X, Ye H, Fu Y. Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a “freeze all” strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg. Fertil Steril. 2017;107(2):379-386 e374. doi:10.1016/j.fertnstert.2016.10.030 Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/27865446.10.1016/j.fertnstert.2016.10.03027865446
- 11. Evans MB, Parikh T, DeCherney AH, Csokmay JM, Healy, MW, Hill MJ. Evaluation of the cost-effectiveness of ovulation suppression with progestins compared with GnRH analogs in assisted reproduction cycles. Reprod Biomed Online. 2019;38(5):691-698. doi:10.1016/j.rbmo.2018.12.044 Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/30926176.10.1016/j.rbmo.2018.12.04430926176
- 12. Iwami N, Kawamata M, Ozawa N, Yamamoto T, Watanabe E, Moriwaka O, Kamiya H. (2018). New trial of progestin-primed ovarian stimulation using dydrogesterone versus a typical GnRH antagonist regimen in assisted reproductive technology. Arch Gynecol Obstet. 2018;298(3):663-671. doi:10.1007/s00404-018-4856-8 Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/30069600.
- 13. La Marca A, Capuzzo M. Use of progestins to inhibit spontaneous ovulation during ovarian stimulation: the beginning of a new era? Reprod Biomed Online. 2019;39(2):321-331. doi:10.1016/j.rbmo.2019.03.212 Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/31138494.10.1016/j.rbmo.2019.03.21231138494